⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10509 | 0.69 | — | — | |
| SCHEMBL10306 | 0.68 | — | — | |
| SCHEMBL2075928 | 0.65 | CHRNB2 (0.42) | — | |
| SCHEMBL14123799 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL2260026 | 0.64 | CHRNB2 (0.41) | — | |
| SCHEMBL164154 | 0.64 | — | — | |
| SCHEMBL3626846 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL2743974 | 0.62 | PNMT (0.39) | — | |
| Hydrochloric Acid SCHEMBL5465421 | 0.62 | PNMT (0.39) | — | |
| SCHEMBL12363790 | 0.62 | CYP2C19 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | claimed |
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | claimed |
| EP-3464279-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-11-24 | — | — | EP | claimed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | claimed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | claimed |
| CN-112368285-A | Pyrrolotriazine compounds and methods of inhibiting TAM kinase | 希洛斯医药品股份有限公司 | 2021-02-12 | — | — | CN | claimed |
| EP-3694860-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | Syros Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | claimed |
| EP-3652174-A1 | TAM KINASE INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2019074962-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | claimed |
| EP-3464279-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2019014513-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | claimed |
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | claimed |
| WO-2017205464-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-30 | — | — | WO | claimed |
| EP-2772484-B1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-06-28 | — | — | EP | claimed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | claimed |
| US-20160015712-A1 | Triazolo[4,5-d]pyrimidine derivatives | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | claimed |
| EP-2964649-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | claimed |
| WO-2014135244-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | claimed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | claimed |
| EP-2772484-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | claimed |